Cytochrome P-450 CYP4A (Alkane 1 Monooxygenase)

A P450 oxidoreductase that catalyzes the hydroxylation of the terminal carbon of linear hydrocarbons such as OCTANES and FATTY ACIDS in the omega position. The enzyme may also play a role in the oxidation of a variety of structurally unrelated compounds such as XENOBIOTICS, and STEROIDS.

Also Known As:

Alkane 1 Monooxygenase; Alkane 1-Hydroxylase; Alkane Hydroxylase; CYP4A; Cytochrome P-450 4A; Cytochrome P-450 IVA; Fatty Acid Omega-Hydroxylase; Laurate Omega-Hydroxylase; Lauric Acid (Omega-1)-Hydroxylase; Lauric Acid Monooxygenase; Lauric Acid Omega-hydroxylase; Omega-1 Hydroxylase; Omega-Hydroxylase; Omega-Lauryl Hydroxylase; Acid Hydroxylase, Lauric; Acid Omega-Hydroxylase, Fatty; Acid Omega-hydroxylase, Lauric; Alkane 1 Hydroxylase; CYP4A, Cytochrome P-450; Cytochrome P 450 4A; Cytochrome P 450 CYP4A; Cytochrome P 450 IVA; Fatty Acid Omega Hydroxylase; Hydroxylase, Alkane; Hydroxylase, Omega-1; Hydroxylase, Omega-Lauryl; Laurate Omega Hydroxylase; Lauric Acid Omega hydroxylase; Omega 1 Hydroxylase; Omega Hydroxylase; Omega Lauryl Hydroxylase; Omega-Hydroxylase, Fatty Acid; Omega-Hydroxylase, Laurate; Omega-hydroxylase, Lauric Acid; P-450 4A, Cytochrome; P-450 CYP4A, Cytochrome; Alkane 1-Monooxygenase; Lauric Acid Hydroxylase

Networked: 109 relevant articles (4 outcomes, 13 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Falck, John R: 12 articles (01/2019 - 07/2004)
2.	Roman, Richard J: 10 articles (01/2021 - 02/2005)
3.	Capdevila, Jorge H: 5 articles (11/2018 - 09/2007)
4.	Eid, Assaad A: 4 articles (01/2022 - 05/2009)
5.	Hardwick, James P: 4 articles (01/2022 - 06/2008)
6.	Fan, Fan: 4 articles (01/2021 - 05/2012)
7.	Yang, Jing: 4 articles (08/2019 - 10/2008)
8.	Song, Byoung-Joon: 3 articles (01/2022 - 01/2009)
9.	Chen, Honglei: 3 articles (08/2019 - 01/2017)
10.	Li, Ying: 3 articles (08/2019 - 10/2008)

Related Diseases

1.	Hypertension (High Blood Pressure) 08/01/2008 - "Cyp4a deficiency causes hypertension in male mice, and a loss-of-function variant (T8590C) of CYP4A11 is associated with hypertension in white individuals. " 06/01/1993 - "The present study examined whether long-term induction of renal fatty acid omega-hydroxylase with clofibrate would alter the development of hypertension in Dahl SS/Jr rats. " 07/01/2014 - "In mice, Cyp4a deficiency results in salt-sensitive hypertension through activation of ENaC. " 12/01/2008 - "These results indicate that the introgression of the CYP4A genes from Lewis rats into the Dahl S rats increases the renal formation of 20-HETE and attenuates the development of hypertension and renal disease." 03/01/2008 - "Eicosanoids produced by CYP4A contribute to the elevated vascular tone in hypertension, but the effects of advanced age on CYP4A modulation of vasoconstriction are unknown. "
2.	Neoplasms (Cancer) 02/01/2005 - "TOH-omega-hydroxylase activity was undetectable in rat primary lung type II cells, suggesting that expression of activity was associated with transformation of normal type II cells to cancer cells. " 01/01/2017 - "In summary, CYP4A in TAMs is crucial for lung pre-metastatic niche formation and metastasis, and may serve as a potential therapeutic target in human cancer." 01/01/1993 - "The expression of CYP4A proteins and mRNAs in these tumors as assessed by Western and Northern blot was undetectable. " 11/01/2018 - "This retrospective analyzes the history of some of these efforts, with emphasis on genetic studies that identified roles for the murine Cyp4a and Cyp2c genes in renal and vascular physiology and the pathophysiology of hypertension and cancer. " 01/01/2017 - "Here, we tested whether a novel flavonoid (FLA-16) prolongs survival and normalizes tumor vasculature in glioma through CYP4A inhibition. "
3.	Inflammation (Inflammations) 01/01/2019 - "Together, inhibition of COX-2, 5-LOX, and CYP4A in macrophages by Sal ameliorates MSU crystal-induced inflammation through decreasing TNF-α and IL-1β production, and may serve as a novel therapeutic strategy." 06/01/2014 - "Murine hepatic Cyp4a mRNAs are markedly downregulated during inflammation. " 01/01/2001 - "Characterization of CYP4A induction in rat liver by inflammatory stimuli: dependence on sex, strain, and inflammation-evoked hypophagia." 05/05/1993 - "Isolation of the cDNA opens the way to investigate the physiological role and to regulation of the omega-hydroxylase in the inflammation process." 12/27/2021 - "Changes in the gene expression of cytochrome P450 enzymes, particularly Cyp4A, can improve hepatic lipid metabolism and moderate inflammation. "
4.	Non-alcoholic Fatty Liver Disease 01/01/2017 - "Here, we showed that hepatic CYP4A expression was up-regulated in the livers of patients and three murine models of NAFLD. " 06/15/2008 - "The differential regulation of the CYP4A and CYP4F genes during fasting, by peroxisome proliferators and in non-alcoholic fatty liver disease (NAFLD) suggests different roles in lipid metabolism. " 01/01/2021 - "We previously reported that cytochrome P450 omega-hydroxylase 4a14 (Cyp4a14) plays an important role in the pathogenesis of non-alcoholic fatty liver disease (NAFLD)-related fibrosis. " 04/01/2000 - "CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis." 01/01/2019 - "The expression and activity of cytochrome P450 4A (CYP4A), a hepatic glucose and lipid homeostasis enzyme, that is highly expressed in liver tissues from NAFLD patients, was induced in our in vitro steatosis model, and inhibiting CYP4A with the selective inhibitor HET0016 or a specific siRNA ameliorated steatosis-related pathology through reduced ER stress and improved insulin signaling. "
5.	Cardiovascular Diseases (Cardiovascular Disease) 11/01/2011 - "These results could be helpful for further investigations of the potential role of CYP4A variants in the genetic susceptibility to cardiovascular diseases in humans such as arterial hypertension." 10/12/2017 - "These alterations induced by Type II diabetes in the endogenous pathway (CYP450) of arachidonic acid metabolism may increase the risk for cardiovascular disease by disrupting the fine equilibrium between cardioprotective (CYP2J/CYP2C-generated) and cardiotoxic (CYP4A/CYP4F-generated) metabolites of arachidonic acid." 10/12/2017 - "Altered Protein Expression of Cardiac CYP2J and Hepatic CYP2C, CYP4A, and CYP4F in a Mouse Model of Type II Diabetes-A Link in the Onset and Development of Cardiovascular Disease?"

Related Drugs and Biologics

1.	Enzymes
2.	20-hydroxy-5,8,11,14-eicosatetraenoic acid
3.	Cytochrome P-450 Enzyme System (Cytochrome P450)
4.	Lipids
5.	HET0016
6.	Glucose (Dextrose)
7.	Small Interfering RNA (siRNA)
8.	Insulin (Novolin)
9.	Arachidonic Acid (Vitamin F)
10.	Salts

Related Therapies and Procedures

1.	Intraperitoneal Injections
2.	Injections
3.	Sodium-Restricted Diet (Diet, Sodium Restricted)